β€’
Mar 31, 2022

Beauty Health Q1 2022 Earnings Report

BeautyHealth delivered strong growth, driven by robust demand and the successful launch of Syndeo, leading to increased full-year guidance.

Key Takeaways

BeautyHealth reported a strong first quarter with net sales increasing by 58.6% to $75.4 million. The company raised its full-year net sales guidance to $330-340 million, reflecting confidence in its growth plan.

Net sales increased by 58.6% to $75.4 million compared to Q1 2021.

Delivery Systems net sales increased to $41.6 million, driven by the successful launch of Syndeo.

Consumables net sales increased to $33.8 million, reflecting continued strong demand.

The company increased its full-year net sales guidance to $330.0 million - $340.0 million.

Total Revenue
$75.4M
Previous year: $47.5M
+58.6%
EPS
-$0.055
Previous year: -$0.03
+83.3%
Gross Margin
68.9%
Previous year: 66.8%
+3.1%
Adjusted EBITDA
$2.22M
Previous year: $7M
-68.3%
Adjusted EBITDA Margin
2.9%
Previous year: 14.8%
-80.4%
Gross Profit
$51.9M
Previous year: $31.7M
+63.8%
Cash and Equivalents
$859M
Previous year: $14.1M
+5993.9%
Free Cash Flow
-$41.6M
Previous year: $443K
-9495.0%
Total Assets
$1.2B
Previous year: $464M
+158.7%

Beauty Health

Beauty Health

Beauty Health Revenue by Segment

Beauty Health Revenue by Geographic Location

Forward Guidance

BeautyHealth increased its fiscal 2022 guidance and now expects net sales in the range of $330.0 million to $340.0 million, up from the previous outlook for $320.0 million to $330.0 million. The Company also reaffirmed its outlook for adjusted EBITDA of approximately $50.0 million.

Positive Outlook

  • Increased full-year net sales guidance to $330.0 million - $340.0 million.
  • Reaffirmed outlook for adjusted EBITDA of approximately $50.0 million.
  • Reflects management's confidence in the business.
  • Company executes against its growth plan.
  • Momentum in health and wellness.

Challenges Ahead

  • Assumes no material deterioration in general market conditions.
  • Assumes no material deterioration or other factors related to COVID-19 trends.
  • Cautious of the potential risk for further market closures or other restrictive measures from existing or new COVID-19 strains.
  • Uneven global rollout and adoption of vaccines.
  • Inflationary headwinds related to higher raw material, shipping and labor costs.

Revenue & Expenses

Visualization of income flow from segment revenue to net income